RecruitingPhase 1NCT05018819

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy


Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Enrollment

15 participants

Start Date

Feb 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Cerebral Palsy


Eligibility

Inclusion Criteria1

  • Diagnosis of Cerebral Palsy

Exclusion Criteria9

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • Clinically significant Abnormalities on pre-treatment laboratory evaluation
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety
  • Previous organ transplant
  • Seizure disorder
  • Hypersensitivity to sulfur

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAlloRx

cultured allogeneic adult umbilical cord derived mesenchymal stem cells


Locations(2)

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Athens Beverly Hills Medical Group

Glyfada, Athens, Greece

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05018819


Related Trials